Skip to main content

Table 1 Patient characteristics

From: Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy

Variable

(N = 69)

n (%)

PSA before prostatectomy (ng/mL), median (range)

10.0 (0.8, 84.0)

Resection margins

 

 R0

31 (44.9%)

 R1

38 (55.1%)

Gleason score

 

  ≤ 7

40 (58.0%)

  ≥ 8

28 (40.6%)

 missing

1 (1,4%)

Tumor classification

 

 pT2a

4 (5.8%)

 pT2b

1 (1.4%)

 pT2c

16 (23.2%)

 pT3a

21 (30.4%)

 pT3b

26 (37.7%)

 pT4

1 (1.4%)

Lymphadenectomy performed

 

 No

9 (13.0%)

 Yes

60 (87.0%)

Lymphnode classification

 

 N0

51 (73.9%)

 N1

18 (26.1%)

Number of lymph nodes removed, median (range)

13.0 (1.0, 51.0)

Persistent PSA 4–12 weeks after prostatectomy

 

  < 0.1 ng/mL

46 (66.7%)

  ≥ 0.1 ng/mL

15 (21.7%)

  < 0.5 ng/ml

54 (78.3%)

  ≥ 0.5 ng/ml

7 (10.1%)

 missing

8 (11.6%)

PSA at start of RT

 

  < 0.5 ng/mL

57 (82.6%)

  ≥ 0.5 ng/mL

12 (17.4%)

Age at start of RT median (range) in years

66 (45, 78)

Time from surgery to RT start, median (range) in months

10.0 (1.0, 155.0)

ECOG performance status at treatment start

 

 0

12 (17.4%)

 1

57 (82.6%)

RT technique

 

 Tomotherapy

69 (100%)

ADT during RT

 

 No

46 (66.7%)

 Yes

23 (33.3%)

Pelvic nodal RT

 

 No

53 (76.8%)

 Yes

16 (23.2%)

  1. Abbreviations: PSA prostate specific antigen, RT radiation therapy, ECOG Eastern
  2. Cooperative Oncology Group, ADT androgen deprivation therapy